Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States.
+ 1 more risk
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Adaptimmune Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ADAP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ADAP exceeded the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: ADAP exceeded the US Market which returned 9.7% over the past year.
Price Volatility Vs. Market
How volatile is Adaptimmune Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StBullish: Analysts Just Made An Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
4 weeks ago | Simply Wall StSome Adaptimmune Therapeutics (NASDAQ:ADAP) Shareholders Have Taken A Painful 79% Share Price Drop
3 months ago | Simply Wall StEarnings Update: Adaptimmune Therapeutics plc Just Reported And Analysts Are Boosting Their Estimates
Is Adaptimmune Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ADAP ($11.25) is trading below our estimate of fair value ($20.18)
Significantly Below Fair Value: ADAP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ADAP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ADAP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADAP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADAP is overvalued based on its PB Ratio (7.9x) compared to the US Biotechs industry average (3.6x).
How is Adaptimmune Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADAP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADAP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADAP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADAP's revenue (56.1% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: ADAP's revenue (56.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADAP's Return on Equity is forecast to be high in 3 years time
How has Adaptimmune Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADAP is currently unprofitable.
Growing Profit Margin: ADAP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADAP is unprofitable, and losses have increased over the past 5 years at a rate of -27% per year.
Accelerating Growth: Unable to compare ADAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADAP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: ADAP has a negative Return on Equity (-74.14%), as it is currently unprofitable.
How is Adaptimmune Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ADAP's short term assets ($227.8M) exceed its short term liabilities ($29.8M).
Long Term Liabilities: ADAP's short term assets ($227.8M) exceed its long term liabilities ($69.4M).
Debt to Equity History and Analysis
Debt Level: ADAP is debt free.
Reducing Debt: ADAP had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADAP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ADAP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Adaptimmune Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADAP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADAP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADAP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ad Rawcliffe (47yo)
Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune ...
CEO Compensation Analysis
Compensation vs Market: Ad's total compensation ($USD2.15M) is below average for companies of similar size in the US market ($USD4.76M).
Compensation vs Earnings: Ad's compensation has increased whilst the company is unprofitable.
|CEO, Principal Accounting Officer & Director||0.75yr||US$2.15m||0.0095% $163.7k|
|Co-Founder & Chief Business Officer||no data||US$1.36m||0.16% $2.7m|
|Chief Operating Officer||3.25yrs||US$1.37m||0.010% $172.4k|
|Chief Financial Officer||0.17yr||no data||no data|
|Vice President of Communications & Investor Relations||no data||no data||no data|
|Head of Public Relations & Company Secretary||no data||no data||no data|
|President of Research & Development||5.25yrs||US$2.60m||no data|
|Senior Vice President of Clinical Development||5.08yrs||no data||no data|
|Head of Biometrics and Vice President||4.75yrs||no data||no data|
|Head of Autoimmune Group||4.42yrs||no data||no data|
Experienced Management: ADAP's management team is considered experienced (4.4 years average tenure).
|CEO, Principal Accounting Officer & Director||0.75yr||US$2.15m||0.0095% $163.7k|
|Independent Chairman of the Board of Directors||3.42yrs||US$129.79k||0.51% $8.7m|
|Non-Executive Director||5.5yrs||US$3.12m||1.43% $24.7m|
|Independent Non-Executive Director||5.33yrs||US$86.69k||0.047% $813.0k|
|Independent Non-Executive Director||4yrs||US$70.86k||no data|
|Independent Non-Executive Director||5.33yrs||US$86.69k||no data|
|Independent Non-Executive Director||5.25yrs||US$130.30k||0.015% $261.1k|
|Independent Non-Executive Director||3.58yrs||US$93.36k||no data|
|Independent Non-Executive Director||1.92yrs||US$88.96k||no data|
Experienced Board: ADAP's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.7%.
Adaptimmune Therapeutics plc's company bio, employee growth, exchange listings and data sources
- Name: Adaptimmune Therapeutics plc
- Ticker: ADAP
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.729b
- Shares outstanding: 153.68m
- Website: https://www.adaptimmune.com
Number of Employees
- Adaptimmune Therapeutics plc
- 60 Jubilee Avenue
- Milton Park
- OX14 4RX
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ADAP||NasdaqGS (Nasdaq Global Select)||Yes||SPONDS ADR||US||USD||May 2015|
|473A||DB (Deutsche Boerse AG)||Yes||SPONDS ADR||DE||EUR||May 2015|
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company’s specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune’s PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/06 05:43|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.